Drug intelligence / Profile preview

Newzen-150

Development stage: Preclinical
Lead developer: NewzenPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Newzen-150 is an investigational **monoclonal antibody** cancer therapy from **NewzenPharma**. Publicly available pipeline information identifies it only as an antibody-based program intended to selectively target cancer cells with precision for oncology use. The specific molecular target, tumor antigen, detailed indication, route of administration, dosage form, and clinical development phase have not been publicly disclosed, so its mechanism can currently only be described at a high level as a targeted antineoplastic antibody approach.

Other names: Newzen-NewzenPharma-monoclonal antibody-cancer

Beyond the preview

Go deeper on Newzen-150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newzen-150.

Explore the full profile